BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

Appeals court upholds Enbrel patents  Amgen Inc. (NASDAQ:AMGN) shares rose 8% Wednesday, adding more than $11 billion to the company’s market cap, after the U.S. Court of Appeals for the Federal Circuit upheld a 2019...
BioCentury | Jul 1, 2020
Regulation

June 30 Quick Takes: Another first for Ultragenyx; plus approvals for Genentech’s Phesgo, Keytruda, Bavencio and Ultomiris

Ultragenyx’s Dojolvi wins FDA approval for rare disease FDA approved Dojolvi triheptanoin (UX007) from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat long-chain fatty acid oxidation disorders, making it the first drug approved for the indication. The...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BioCentury | Jun 26, 2020
Product Development

Pfizer, BioNTech on track to make hundreds of millions of COVID-19 vaccine doses this year

Pfizer and its partner BioNTech could obtain emergency use authorization for a COVID-19 vaccine as early as October, and expect to be able to produce hundreds of millions of doses in 2020 and a billion...
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

Among a trio of companies making their NASDAQ debuts on Friday, Akouos’ first-day rise of 29% was the biggest, while Fusion gave back its early gains and PolyPid also climbed in the aftermarket. Across the...
BioCentury | Jun 24, 2020
Product Development

Action needed to prevent manufacturing bottlenecks on COVID-19 therapies

Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars. A...
BioCentury | Jun 17, 2020
Politics, Policy & Law

COVAX created to try to avoid global bidding frenzy for COVID-19 vaccines

Panic buying of vaccines by high income countries, mopping up supply and squeezing out lower income countries, is the nightmare postscript to COVID-19 that international health agencies envisage could play out if steps aren’t taken...
BioCentury | Jun 13, 2020
Product Development

ACTIV coming into focus, starting COVID-19 therapy trials in June

A consortium that is pooling the resources of the U.S. government and global biopharmaceutical companies to discover and develop drugs and vaccines for COVID-19 has selected a first wave of therapies for testing and plans...
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | Jun 12, 2020
Finance

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

Biotech tumbles as U.S. indexes plunge  Biotech indexes fell along with the broader markets Thursdays in a sell-off sparked by fears of an increase in COVID-19 infections. The NASDAQ Composite, S&P 500 and Dow Jones...
Items per page:
1 - 10 of 8855
BioCentury | Jul 2, 2020
Product Development

July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

Appeals court upholds Enbrel patents  Amgen Inc. (NASDAQ:AMGN) shares rose 8% Wednesday, adding more than $11 billion to the company’s market cap, after the U.S. Court of Appeals for the Federal Circuit upheld a 2019...
BioCentury | Jul 1, 2020
Regulation

June 30 Quick Takes: Another first for Ultragenyx; plus approvals for Genentech’s Phesgo, Keytruda, Bavencio and Ultomiris

Ultragenyx’s Dojolvi wins FDA approval for rare disease FDA approved Dojolvi triheptanoin (UX007) from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat long-chain fatty acid oxidation disorders, making it the first drug approved for the indication. The...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...
BioCentury | Jun 26, 2020
Product Development

Pfizer, BioNTech on track to make hundreds of millions of COVID-19 vaccine doses this year

Pfizer and its partner BioNTech could obtain emergency use authorization for a COVID-19 vaccine as early as October, and expect to be able to produce hundreds of millions of doses in 2020 and a billion...
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

Among a trio of companies making their NASDAQ debuts on Friday, Akouos’ first-day rise of 29% was the biggest, while Fusion gave back its early gains and PolyPid also climbed in the aftermarket. Across the...
BioCentury | Jun 24, 2020
Product Development

Action needed to prevent manufacturing bottlenecks on COVID-19 therapies

Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars. A...
BioCentury | Jun 17, 2020
Politics, Policy & Law

COVAX created to try to avoid global bidding frenzy for COVID-19 vaccines

Panic buying of vaccines by high income countries, mopping up supply and squeezing out lower income countries, is the nightmare postscript to COVID-19 that international health agencies envisage could play out if steps aren’t taken...
BioCentury | Jun 13, 2020
Product Development

ACTIV coming into focus, starting COVID-19 therapy trials in June

A consortium that is pooling the resources of the U.S. government and global biopharmaceutical companies to discover and develop drugs and vaccines for COVID-19 has selected a first wave of therapies for testing and plans...
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

The American Association for Cancer Research elected Charles Sawyers as president; he will assume the role during AACR’s 2021 meeting, which will take place in Washington on April 9-14. Sawyers is chair of Memorial Sloan...
BioCentury | Jun 12, 2020
Finance

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

Biotech tumbles as U.S. indexes plunge  Biotech indexes fell along with the broader markets Thursdays in a sell-off sparked by fears of an increase in COVID-19 infections. The NASDAQ Composite, S&P 500 and Dow Jones...
Items per page:
1 - 10 of 8855